Skip to content

Study · Not a test of the peptide alone · 2016

4 results

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.

de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K

International journal of clinical pharmacy23 Nov 2015Cited by 26 (Europe PMC)

PMID26597956 (opens in a new tab)PMCIDPMC4733138 (opens in a new tab)DOI10.1007/s11096-015-0219-8 (opens in a new tab)PepBankPUB-26597956
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies.ObjectiveTo evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour.SettingThe Martini Hospital and the University Medical Center in Groningen in the Netherlands.MethodsEligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose.Results151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2-8.9) to 7.6 (6.9-8.3) % [63 (55-74) to 60 (52-67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56-150) to 60 (0-100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (-3.1 %) and restrained (n = 41) in the greatest (-10.3 %) in comparison with emotional (n = 37, -8.5 %) and indifferent (n = 25, -9.6 %) eating behaviours.ConclusionTwo year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese adults with insulin-using type 2 diabetes, pooled GLP-1 receptor agonist treatment (exenatide or liraglutide) lowered body weight over 2 years in a real-life setting.

    In plain wordsIn obese adults on insulin with type 2 diabetes, weight fell over two years with a GLP-1 drug, exenatide or liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change over 2 years
    Study

    n = 120

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Body weight
    117.9 kg
    baseline
    Body weight
    107.9 kg
    2 years

    Source sentences

    Summary
    body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001)
    2 context sentences
    Summary · context
    Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment.
    Summary · context
    151 Patients started with exenatide or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese adults with insulin-using type 2 diabetes, pooled GLP-1 receptor agonist treatment (exenatide or liraglutide) lowered HbA1c over 2 years in a real-life setting.

    In plain wordsIn obese adults on insulin with type 2 diabetes, HbA1c fell over two years with a GLP-1 drug, exenatide or liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change over 2 years
    Study

    n = 120

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    7.9%
    baseline, median
    HbA1c
    7.6%
    2 years, median

    Source sentences

    Summary
    HbA1c (median, IQR) changed from 7.9 (7.2-8.9) to 7.6 (6.9-8.3) % [63 (55-74) to 60 (52-67) mmol/mol] (P < 0.0001)
    2 context sentences
    Summary · context
    Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment.
    Summary · context
    151 Patients started with exenatide or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese adults with insulin-using type 2 diabetes, pooled GLP-1 receptor agonist treatment (exenatide or liraglutide) lowered the total daily insulin dose over 2 years in a real-life setting.

    In plain wordsIn obese adults on insulin with type 2 diabetes, the daily insulin dose fell over two years with a GLP-1 drug, exenatide or liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal daily insulin dose change over 2 years
    Study

    n = 120

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Total daily insulin dose
    90 Units/day
    baseline, median
    Total daily insulin dose
    60 Units/day
    2 years, median

    Source sentences

    Summary
    total daily insulin dose changed from 90 (56-150) to 60 (0-100) Units/day (P < 0.0001)
    2 context sentences
    Summary · context
    Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment.
    Summary · context
    151 Patients started with exenatide or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In obese adults with insulin-using type 2 diabetes on pooled GLP-1 receptor agonists (exenatide or liraglutide), weight change differed between eating behaviour groups, with the smallest decline in external eating (-3.1 %) and the greatest in restrained eating (-10.3 %).

    In plain wordsIn obese adults on insulin, weight loss on GLP-1 drugs was linked to eating style: smallest with external eating, greatest with restrained eating.

    Peptide
    Liraglutide
    Outcome
    MixedWeight change by eating behaviour group
    Study

    n = 120

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −3.1%
    external eating
    Weight change
    −10.3%
    restrained eating
    Weight change
    −8.5%
    emotional eating
    Weight change
    −9.6%
    indifferent eating

    Source sentences

    Summary
    Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (-3.1 %) and restrained (n = 41) in the greatest (-10.3 %) in comparison with emotional (n = 37, -8.5 %) and indifferent (n = 25, -9.6 %) eating behaviours.
    2 context sentences
    Summary · context
    Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment.
    Summary · context
    151 Patients started with exenatide or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.